BioSpace News Archive

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022.

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new, post-hoc analysis of data from the Phase 3 EMPOWUR trial of GEMTESA (vibegron) 75 mg in the International Journal of Clinical Practice.

Researchers at Arthritis Research Canada have found that people with osteoarthritis who started taking tramadol, an opioid pain medication, were at a 20-50 per cent greater risk of mortality, 70 per cent greater risk of blood clots, and 40-60 per cent greater risk of hip fractures when compared to people who started using drugs like aspirin or ibuprofen.

Paradigm Biopharmaceuticals, a global biopharmaceutical company specializing in repurposing existing drugs for unmet medical needs, announced their retention of Rubenstein Public Relations as its agency of record.

Endpoint Health, Inc., today announced new retrospective analyses that provide additional insights into the company’s artificial intelligence-driven approach to identifying biologically-distinct groups within diseases predictive of outcomes of different treatment strategies in adults with acute respiratory distress syndrome (ARDS).

Trauma devices are one of the different clinical strategies utilized for the treatment of injury in view of the seriousness of injury.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release first quarter financial results after the close of trading on Tuesday, May 3, 2022.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Treadwell Therapeutics announced today the appointment of J.D. Mowery as Chief Operating Officer (COO).

Keymed Biosciences announced that the U.S. Food and Drug Administration granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.